Panelists discuss how multidisciplinary care for refractory metastatic colorectal cancer involves collaborative decision-making through tumor boards, specialized oral oncology pharmacists for financial assistance and patient support, transitions of care teams, and independent pharmacist-patient conversations that often reveal concerns patients won’t share with prescribers, while emphasizing that balancing survival extension with quality of life requires understanding individual patient desires and life goals, incorporating patient values into treatment decisions by assessing their tolerance for side effects and supportive care burden, and recognizing that what’s clinically meaningful to providers may differ significantly from what matters most to each individual patient.